Interleukin-6 polymorphisms and gender: Relationship with the occurrence of hepatocellular carcinoma in patients with end-stage liver disease

Oncology

Volumn 77, Issue 5, 2009, Pages 304-313

  Falleti, Edmondo ^a   Fabris, Carlo ^a   Toniutto, Pierluigi ^a   Fontanini, Elisabetta ^a   Cussigh, Annarosa ^a   Bitetto, Davide ^a   Fumolo, Elisa ^a   Fornasiere, Ezio ^a   Bragagnini, Walter ^a   Pinato, David J ^b   Minisini, Rosalba ^b   Pirisi, Mario ^b  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Gender; Hepatocellular carcinoma; Interleukin 6 polymorphisms; Liver cirrhosis

Indexed keywords

INTERLEUKIN 6;

ADULT; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; DIPLOIDY; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER INJURY; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TISSUE SECTION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INTERLEUKIN-6; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SEX FACTORS;

EID: 70450184559     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000260057     Document Type: Article

References (44)

1. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
2. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
3. Llovet JM, Beaugrand M: Hepatocellular carcinoma: present status and future prospects. J Hepatol 2003; 38(suppl 1):S136-S149.
4. Bosch FX, Ribes J, Diaz M, Cleries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127:S5-S16.
5. Parikh S, Hyman D: Hepatocellular cancer: a guide for the internist. Am J Med 2007; 120: 194-202.
6. Fattovich G, Stroffolini T, Zagni I, Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127:S35-S50.
7. Nakatani T, Roy G, Fujimoto N, Asahara T, Ito A: Sex hormone dependency of diethylnitrosamine-induced liver tumors in mice and chemoprevention by leuprorelin. Jpn J Cancer Res 2001; 92: 249-256.
8. Mantovani A: Cancer: an infernal triangle. Nature 2007; 448: 547-548.
9. Sander LE, Trautwein C, Liedtke C: Is interleukin-6 a gender-specific risk factor for liver cancer? Hepatology 2007; 46: 1304-1305.
10. Wands J: Hepatocellular carcinoma and sex. N Engl J Med 2007; 357: 1974-1976.
11. Lawrence T, Hageman T, Balkwill F: Cancer. Sex, cytokines, and cancer. Science 2007; 317: 51-52.
12. Prieto J: Inflammation, HCC and sex: IL-6 in the centre of the triangle. J Hepatol 2008; 48: 380-381.
13. Stein B, Yang MX: Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κ B and C/EBPβ . Mol Cell Biol 1995; 15: 4971-4979.
14. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M: Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121-124.
15. Qi L, van Dam RM, Meigs JB, Manson JE, Hunter D, Hu FB: Genetic variation in IL6 gene and type 2 diabetes: tagging-SNP haplotype analysis in large-scale case-control study and meta-analysis. Hum Mol Genet 2006; 15: 1914-1920.
16. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-1376.
17. Belluco C, Olivieri F, Bonafe M, Giovagnetti S, Mammano E, Scalerta R, Ambrosi A, Franceschi C, Nitti D, Lise M: -174 G>1 C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin Cancer Res 2003; 9: 2173-2176.
18. Hefler LA, Grimm C, Ackermann S, Malur S, Radjabi-Rahat AR, Leodolter S, Beckmann MW, Zeillinger R, Koelbl H, Tempfer CB: An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res 2003; 63: 3066-3068.
19. Tan D, Wu X, Hou M, Lee SO, Lou W, Wang J, Janarthan B, Nallapareddy S, Trump DL, Gao AC: Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol 2005; 174: 753-756.
20. Park BL, Lee HS, Kim YJ, Kim JY, Jung JH, Kim LH, Shin HD: Association between interleukin 6 promoter variants and chronic hepatitis B progression. Exp Mol Med 2003; 35: 76-82.
21. Migita K, Miyazoe S, Maeda Y, Daikoku M, Abiru S, Ueki T, Yano K, Nagaoka S, Matsumoto T, Nakao K, Hamasaki K, Yatsuhashi H, Ishibashi H, Eguchi K: Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection - association between TGF-β 1 polymorphisms and hepatocellular carcinoma. J Hepatol 2005; 42: 505-510.
22. Excoffier L, Laval G, Schneider S: Arlequin (version 3.0): An integrated software package for population genetics data analysis. Evol Bioinform Online 2005; 1: 47-50.
23. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
24. Hirano T: Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998; 16: 249-284.
25. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374: 1-20.
26. Scheller J, Rose-John S: Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol 2006; 195: 173-183.
27. Naugler WE, Karin M: The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008; 14: 109-119.
28. Berger FG: The interleukin-6 gene: a susceptibility factor that may contribute to racial and ethnic disparities in breast cancer mortality. Breast Cancer Res Treat 2004; 88: 281-285.
29. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M: Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000; 6: 2702-2706.
30. Chung YC, Chang YF: Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 2003; 83: 222-226.
31. Giannitrapani L, Cervello M, Soresi M, Notarbartolo M, La Rosa M, Virruso L, D'Alessandro N, Montalto G: Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma. Ann NY Acad Sci 2002; 963: 46-52.
32. Ataseven H, Bahcecioglu IH, Kuzu N, Yalniz M, Celebi S, Erensoy A, Ustundag B: The levels of ghrelin, leptin, TNF-α , and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection. Mediators Inflamm 2006; 2006: 78380.
33. Soresi M, Giannitrapani L, D'Antona F, Florena AM, La Spada E, Terranova A, Cervello M, D'Alessandro N, Montalto G: Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 2006; 12: 2563-2568.
34. Porta C, De Amici M, Quaglini S, Paglino C, Tagliani F, Boncimino A, Moratti R, Corazza GR: Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol 2008; 19: 353-358.
35. Cox ED, Hoffmann SC, DiMercurio BS, Wesley RA, Harlan DM, Kirk AD, Blair PJ: Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation 2001; 72: 720-726.
36. Meenagh A, Williams F, Ross OA, Patterson C, Gorodezky C, Hammond M, Leheny WA, Middleton D: Frequency of cytokine polymorphisms in populations from western Europe, Africa, Asia, the Middle East and South America. Hum Immunol 2002; 63: 1055-1061.
37. De-Madaria E, Martinez J, Sempere L, Lozano B, Sanchez-Paya J, Uceda F, Perez-Mateo M: Cytokine genotypes in acute pancreatitis: association with etiology, severity, and cytokine levels in blood. Pancreas 2008; 37: 295-301.
38. Gordon A, Kiss-Toth E, Stockley I, Eastell R, Wilkinson JM: Polymorphisms in the interleukin-1 receptor antagonist and interleukin-6 genes affect risk of osteolysis in patients with total hip arthroplasty. Arthritis Rheum 2008; 58: 3157-3165.
39. Ambruzova Z, Mrazek F, Raida L, Jindra P, Vidan-Jeras B, Faber E, Pretnar J, Indrak K, Petrek M: Association of IL6 and CCL2 gene polymorphisms with the outcome of allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2009.
40. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002; 420: 860-867.
41. Kuper H, Adami HO, Trichopoulos D: Infections as a major preventable cause of human cancer. J Intern Med 2000; 248: 171-183.
42. Karin M, Greten FR: NF-κ B: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-759.
43. Li Q, Withoff S, Verma IM: Inflammationassociated cancer: NF-κ B is the lynchpin. Trends Immunol 2005; 26: 318-325.
44. Barrett S, Collins M, Kenny C, Ryan E, Keane CO, Crowe J: Polymorphisms in tumour necrosis factor-α , transforming growth factor-β , interleukin-10, interleukin-6, interferonγ , and outcome of hepatitis C virus infection. J Med Virol 2003; 71: 212-218.